1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Beijing Succeeder Technology, Inc. Class A

Beijing Succeeder Technology, Inc. Class A

SSSE:688338
27.41
CNY
+0.34
(+1.26%)
0.89EPS
33.01P/E
3.13BMarket Cap
Beijing Succeeder Technology, Inc. Class A
SSE:688338
(Shanghai Stock Exchange)

Recent

price

27.41

P/E

ratio

33.01

div

yld

0.00%

ROIC.AI

2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.77
2.14
2.71
2.96
2.45
2.26
2.15
2.59
2.9
2.5
2.62
Revenue per Share
0.44
0.4
0.77
0.92
0.76
0.92
0.98
1.1
1.07
0.85
0.89
Basic EPS, GAAP
0.44
0.41
0.74
0.72
0.44
0.86
0.03
-0.1
0.48
0.43
- -
Free Cash Flow per Basic Share
0.05
0.26
0.05
0.01
0.13
0.31
0.19
0.2
0.26
0.33
- -
Dividend per Share
1.48
1.94
2.65
4.71
12.78
13.39
14.17
15.08
15.51
15.92
16.07
Book Value per Share
1.47
1.93
2.64
4.7
12.51
13.13
13.93
14.85
15.29
15.72
15.88
Tangible Book Value per Share
71
73
74
78
91
106
106
106
106
105
103
Basic Weighted Avg Shares
125
157
200
230
222
240
229
275
306
263
271
Sales/Revenue/Turnover
26.27
23.78
31.79
33.71
34.54
34.24
36.24
37.79
33.73
32
33.29
Operating Margin (%)
2
2
3
3
4
8
7
5
12
13
- -
Depreciation Expense
31
29
57
71
69
97
104
117
113
90
92
Net Income, GAAP
13.05
16.02
13.37
13.04
13.35
13.27
13.15
13.32
12.99
13.2
12.34
Effective Tax Rate (%)
24.74
18.73
28.34
30.95
31.11
40.58
45.5
42.44
36.94
34.04
34.12
Profit Margin (%)
65
103
154
331
1,282
1,328
1,292
1,278
1,281
1,331
1,352
Working Capital
- -
- -
- -
- -
4
1
- -
- -
- -
- -
- -
LT Debt
104
143
196
375
1,356
1,421
1,505
1,600
1,646
1,690
1,705
Total Equity
- -
23.25
32.35
24.42
8.41
6.7
6.93
7.48
6.94
5.37
5.5
Return on Invested Capital (%)
- -
23.8
32.41
23.49
7.17
7
7.11
7.53
6.96
5.38
5.5
Return on Capital (%)
- -
23.75
33.46
24.91
7.99
7.01
7.12
7.53
6.96
5.37
5.5
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
106
106
106
Market Capitalization
2,747
3,126
3,132

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,406
1,421
1,417
Cash, Cash Equivalents & STI
1,280
1,301
1,290
Accounts Receivable, Net
54
47
59
Inventories
42
43
38
Total Current Liabilities
75
68
65
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
4.51%
2.64%
Free Cash Flow
- -
-194.91%
-9.59%
Net Income, GAAP
- -
7.18%
-20.71%
Sales/Revenue/Turnover
- -
4.15%
-13.94%
Total Cash Common Dividend
- -
38.6%
24.33%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
76
83
67
79
306
2025
69
70
- -
68
263
2026
60
73
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.29
0.3
0.2
0.28
1.07
2025
0.22
0.24
- -
0.24
0.85
2026
0.19
0.22
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.26
2025
- -
- -
- -
- -
0.33
2026
- -
- -
- -
- -
- -
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Beijing Succeeder Technology Inc. specializes in the research, development, manufacture, and sale of in-vitro diagnostic products focused on thrombosis and hemostasis. Its core product portfolio includes automated coagulation analyzers, coagulation reagents, hemorheology analyzers, erythrocyte sedimentation rate (ESR) analyzers, hematocrit analyzers, and platelet aggregation analyzers. These products are designed for prevention, screening, diagnosis, and monitoring of thrombotic and bleeding disorders such as thrombophilia, coronary heart disease, and venous thromboembolism. The company also supplies original reagents, consumables, and controls tailored for different laboratory sizes and testing requirements, holding certifications including ISO 13485, CE, and FDA listings. Founded in 2003 and headquartered in Beijing, China, Beijing Succeeder operates in both domestic and international markets, serving over 7,000 installed users worldwide. Recent major developments include the company's receipt of the national specialized, special, and new "Little Giant" enterprise certificate from the Chinese Ministry of Industry and Information Technology valid through June 2027, highlighting its status as an innovative specialist in its field. Beijing Succeeder reported a revenue increase of 11.03% year-on-year in 2024 with revenues of 0.306 billion yuan, despite a slight 3.35% decline in net income. The company undertook significant share repurchases amounting to 2.05% of its total share capital, evidencing confidence in its financial standing. It remains focused on technological monitoring, having stated that as of early 2025 its products have not yet integrated with AI platforms like DeepSeek, but it continues tracking AI advancements for future potential integration. Additionally, Beijing Succeeder participates actively in regional industry exhibitions such as Medlab Middle East 2024, reinforcing its strategic marketing and expansion efforts. The company leverages a broad research and development capability alongside production, marketing, and after-sales service operations. It targets medical institutions with laboratories requiring coagulation and hemostasis diagnostics while maintaining compliance with international standards. Beijing Succeeder's product design emphasizes automation, advanced assay methods including viscosity-based, immunoturbidimetric, and chromogenic assays, and laboratory information system (LIS) integration, supporting both large and small-to-medium-level labs. This comprehensive approach positions Beijing Succeeder as a recognized leader in China's diagnostic market for thrombosis and hemostasis products, with a growing international footprint.